News
GRTX
0.2075
+13.57%
0.0248
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Moolec Science stock is rocketing more than 67% on approval for its plant-groan animal proteins. Vaxxinity stock is crashing more than 55% on the company's plans to delist its shares. The biggest pre-market stock movers for Monday morning are earnings, investments, a delisting and more.
Investorplace · 4d ago
Weekly Report: what happened at GRTX last week (0415-0419)?
Weekly Report · 4d ago
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Mobile-health Network (NASDAQ:MNDR) shares rose 15.0% to $31.35 during Friday's after-market session. The company's market cap stands at $1.0 billion. China Pharma Holdings, Inc. Common Stock (AMEX:CPHI) stock moved upwards by 6.7%.
Benzinga · 6d ago
12 Health Care Stocks Moving In Wednesday's Intraday Session
INVO Bioscience stock rose 275.0% to $2.85 during Wednesday's regular session. The company's Q4 earnings report came out yesterday. Vanda Pharma stock moved upwards by 33.33% during the session. Losers include Longeveron (NASDAQ:LGVN) and Dare BiosScience.
Benzinga · 04/17 16:31
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
INVO Bioscience shares increased by 93.4% to $1.47 during Wednesday's pre-market session. The company's, Q4 earnings came out yesterday. Clene shares moved upwards by 40.8% and Galera Therapeutics shares moved up by 31.6%. Sage Therapeutic (NASDAQ:SAGE) stock decreased by 19.4%.
Benzinga · 04/17 12:08
Weekly Report: what happened at GRTX last week (0408-0412)?
Weekly Report · 04/15 09:32
Weekly Report: what happened at GRTX last week (0401-0405)?
Weekly Report · 04/08 09:34
Why Doma Holdings Shares Are Trading Higher By Around 34%; Here Are 20 Stocks Moving Premarket
Shares of Doma Holdings Inc. Rose sharply in today’s pre-market trading. The company entered a merger transaction with TRG to go private at $6.29 per share in cash. Vast Renewables Limited shares rose 213.9% to $9.70 after jumping 39% on Thursday.
Benzinga · 04/01 12:08
12 Health Care Stocks Moving In Monday's Pre-Market Session
Galera Therapeutics (NASDAQ:GRTX) shares moved upwards by 62.8% to $0.23 during Monday's pre-market session. China Pharma Holdings, Inc. Common Stock (AMEX:CPHI) stock rose 14.76% in the pre- market session. Sunshine Biopharma ( NASDAQ:SBFM) shares also rose.
Benzinga · 04/01 12:08
Weekly Report: what happened at GRTX last week (0325-0329)?
Weekly Report · 04/01 09:33
12 Health Care Stocks Moving In Friday's After-Market Session
Qilian Intl Hldg Gr (NASDAQ:QLI) shares rose 63.8% to $1.04 during Friday's after-market session. Sunshine Biopharma stock moved upwards by 39.5% as the company's market cap rose to $8.3 million. Xilio Therapeutics and Medpace Hldgs also rose in the wake of Q4 earnings.
Benzinga · 03/29 20:30
Galera Therapeutics GAAP EPS of -$0.10
Seeking Alpha · 03/28 18:58
GRTX Stock Earnings: Galera Therapeutics Beats EPS for Q4 2023
Galera Therapeutics reported earnings per share of -10 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. This was above the analyst estimate for EPS of -35 cents. GaleraTherapeutics just reported results.
Investorplace · 03/28 15:53
Galera Therapeutics: Q4 Earnings Insights
Galera Therapeutics reported its Q4 earnings results on March 28. The company beat estimates by 71.0%. The company's revenue was down $0 from the same period last year. The stock rose 3.0% the next day after the announcement. GaleraTherapeutics is expected to report its earnings on April 28.
Benzinga · 03/28 11:45
Galera Therapeutics Q4 EPS $(0.10) Beats $(0.35) Estimate
Benzinga · 03/28 11:15
*Galera Therapeutics 4Q Loss/Shr 10c >GRTX
Dow Jones · 03/28 11:00
*Galera Therapeutics 4Q Loss $5.59M >GRTX
Dow Jones · 03/28 11:00
Press Release: Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates
Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates Company continues to evaluate strategic options to maximize shareholder value. Galera is a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics for radiotherapy in cancer. The company announced financial results for the fourth quarter and year ended December 31, 2023.
Dow Jones · 03/28 11:00
Press Release: Galera Reports Fourth Quarter and -2-
Risk Factors include risks relating to the regulatory approval process in the U.S. And other jurisdictions. Galera may not be able to enter into any desired strategic alternative or partnership. The company may need to cease operations; risks related to ownership of Galera's common stock; and significant costs as a result of operating as a public company.
Dow Jones · 03/28 11:00
*Galera Therapeutics 4Q Research and Development Expenses $3.2M >GRTX
Dow Jones · 03/28 11:00
More
Webull provides a variety of real-time GRTX stock news. You can receive the latest news about Galera Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About GRTX
Galera Therapeutics, Inc. is a biopharmaceutical company focused on developing a pipeline of novel, therapeutic candidates that have the potential to transform radiotherapy in cancer. The Company’s lead product candidate, avasopasem manganese (avasopasem), is a highly selective small molecule dismutase mimetic that the Company is developing for the reduction of severe oral mucositis (SOM) in patients with head and neck cancer (HNC), the reduction of esophagitis in patients with lung cancer, and the reduction of cisplatin-induced kidney damage in patients with cancer. The Company’s second product candidate, rucosopasem manganese (rucosopasem), is in development to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. Rucosopasem is an orphan drug designation and orphan medicinal product designation for the treatment of pancreatic cancer.